Denali Therapeutics (DNLI) Investor Day 2025 summary

Strategic Vision and Platform Innovation

• Expanded focus from neurodegeneration to whole-body biotherapeutics, leveraging the transferrin receptor-enabled TransportVehicle (TV/Tivi) platform for systemic delivery across the blood-brain barrier (BBB), enabling new therapeutic areas and broad clinical applications.

• TV platform includes Enzyme TV (ETV), Antibody TV (ATV), and Oligonucleotide TV (OTV), supporting best-in-class BBB delivery, modularity, and manufacturability, with over 11,000 doses administered and more than 350 patents/applications.

• D3 strategy (Discover, Develop, Deliver) sets three-year goals: building two brands (Tivi and DNL126), achieving five clinical proof-of-concept milestones, and launching four to six new clinical-stage programs, aiming for blockbuster potential across franchises.

• Partnerships and capital efficiency are prioritized, highlighted by a $275M Royalty Pharma deal to support launches and pipeline expansion.

• TV is the most clinically validated BBB technology, with demonstrated ability to correct neurodegeneration and broad clinical experience.

Pipeline, Clinical Progress, and Near-term Launches

• Two near-term launches: tividenofusp alfa (Tivi/DNL310) for MPS II in 2026 and DNL126 for MPS IIIA in 2027, establishing the ETV franchise.

• Tividenofusp alfa has shown normalization of key biomarkers and clinical improvements in MPS II, with a BLA filed for accelerated approval and a PDUFA date of April 5, 2026.

• DNL126 achieved biomarker proof-of-concept in MPS IIIA, with Phase 1/2 enrollment completed and Phase 3 protocol in development; BLA submission expected in 2027.

• Deep pipeline includes programs for Alzheimer's, Parkinson's, Pompe (DNL952), Gaucher, FTD-GRN (DNL593), and more, with several IND-enabling and clinical-stage assets.

• Over 10 preclinical programs and three IND-enabling molecules are in development, focusing on modularity and broad CNS delivery.

Commercial Strategy, Manufacturing, and Patient Impact

• ETV franchise targets lysosomal storage disorders with a combined market opportunity exceeding $1B for the first two launches and $5B+ total.

• Launch strategy for Tivi emphasizes strong community partnerships, streamlined reimbursement, and broad access, with premium pricing balanced by affordability and value.

• U.S. market for MPS II estimated at 400–500 patients, with 50% covered by Medicaid; global expansion targets 60% of addressable market pre-EU launch.

• Integrated in-house manufacturing in Salt Lake City enables faster, more flexible, and cost-effective production, reducing COGS and accelerating IND timelines.

• Patient and caregiver voices highlight the urgent unmet need for therapies that address both CNS and peripheral manifestations, with high anticipation for Tivi's approval.